Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 9/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 8/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6759093 | 1.00 | LTB4R (0.53) | LTB4RSUCNR1ITGB3ITGA2BGPR34 | |
| SCHEMBL6760729 | 0.96 | SUCNR1 (0.54) | LTB4RSUCNR1ITGB3ITGA2B | |
| SCHEMBL6760730 | 0.96 | SUCNR1 (0.54) | LTB4RSUCNR1ITGB3ITGA2B | |
| SCHEMBL6755968 | 0.88 | LTB4R (0.57) | LTB4RSUCNR1ITGB3ITGA2B | |
| SCHEMBL6759717 | 0.86 | ITGB3 (0.59) | LTB4RSUCNR1ITGB3ITGA2B | |
| SCHEMBL6758949 | 0.84 | LTB4R (0.66) | LTB4RGPR34 | |
| SCHEMBL6758951 | 0.84 | LTB4R (0.66) | LTB4RGPR34 | |
| SCHEMBL7300050 | 0.80 | ITGB3 (0.61) | SUCNR1ITGB3ITGA2B | |
| SCHEMBL7298204 | 0.80 | ITGB3 (0.61) | SUCNR1ITGB3ITGA2B | |
| SCHEMBL7327782 | 0.79 | ITGB3 (0.69) | SUCNR1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6770259-B2 | ADMINISTEING RADIOLABELED LEUKOTRIENE (LTB4) BINDING AGENT AND A RADIOLABELED PERFUSION IMAGING AGENT; CONCURRENTLY DETECTING THE RADIOLABELED LTB4 BINDING AGENT BOUND AT THE LTB4 RECEPTOR AND THE RADIOLABELED PERFUSION IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
| EP-0999856-B1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885SUCNR1 1079/4885ITGB3 259/4885 |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | LTB4R 1/4885SUCNR1 1079/4885ITGB3 259/4885 |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885SUCNR1 1706/4885ITGB3 260/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | LTB4R 1/4885SUCNR1 1706/4885ITGB3 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.